Lymphoma Heavyweights Launch New Partnership

The Leukemia & Lymphoma Society (LLS), the Lymphoma Research Foundation (LRF), CancerCare, the Association of Community Cancer Centers (ACCC) and Genentech have announced a new partnership in hopes of connecting the lymphoma community under one banner.

Together they have launched the "Alliance for Resource Collaboration in Hematology" (ARCH), found at www.LymphomaResources.com.

"Many people diagnosed with lymphoma, particularly in community cancer programs, are unaware of all the resources available to them," said Louis J. DeGennaro, Ph.D., LLS's president and chief executive officer. "With this new initiative, our goal is to empower people with lymphoma to be active partners in their care and ensure they don't feel isolated in their journey."

By visiting the website, people can connect to the partner organizations to learn about the different types of lymphoma, explore treatment options, find information about specialists and search financial support options. The ARCH website also helps people find patient communities, peer support programs and counseling services. The partner organizations provide these resources in a variety of formats, including in-person programs, online materials and telephone support.

It's estimated that only 15 percent of U.S. cancer patients are treated at the nation's major academic cancer centers. The vast majority receive care at cancer programs in or near their home communities, where resources may be more limited. By bringing together ACCC's network of community cancer programs with the quality resources provided by LLS, LRF and CancerCare, ARCH aims to make an immediate positive impact for lymphoma patients.

Source: PR Newswire

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap